These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 21691273)

  • 1. Regulatory science as a bridge between science and society.
    Tominaga T; Asahina Y; Uyama Y; Kondo T
    Clin Pharmacol Ther; 2011 Jul; 90(1):29-31. PubMed ID: 21691273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacology and the catalysis of regulatory science: opportunities for the advancement of drug development and evaluation.
    Zineh I; Woodcock J
    Clin Pharmacol Ther; 2013 Jun; 93(6):515-25. PubMed ID: 23571772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The EMEA guideline on first-in-human clinical trials and its impact on pharmaceutical development.
    Milton MN; Horvath CJ
    Toxicol Pathol; 2009 Apr; 37(3):363-71. PubMed ID: 19246571
    [No Abstract]   [Full Text] [Related]  

  • 4. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006.
    Wang Y; Bhattaram AV; Jadhav PR; Lesko LJ; Madabushi R; Powell JR; Qiu W; Sun H; Yim DS; Zheng JJ; Gobburu JV
    J Clin Pharmacol; 2008 Feb; 48(2):146-56. PubMed ID: 18199891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ASCPT Task Force for advancing pharmacometrics and integration into drug development.
    Goldberger MJ; Singh N; Allerheiligen S; Gobburu JV; Lalonde R; Smith B; Ryder S; Yozviak A
    Clin Pharmacol Ther; 2010 Aug; 88(2):158-61. PubMed ID: 20648032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacometrics at FDA: evolution and impact on decisions.
    Powell JR; Gobburu JV
    Clin Pharmacol Ther; 2007 Jul; 82(1):97-102. PubMed ID: 17538553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory watch: impact of PDUFA on regulatory decision-making.
    Hay M
    Nat Rev Drug Discov; 2010 Aug; 9(8):585. PubMed ID: 20671755
    [No Abstract]   [Full Text] [Related]  

  • 9. Transatlantic regulatory cooperation expanded.
    Hughes B
    Nat Rev Drug Discov; 2007 Aug; 6(8):589-90. PubMed ID: 17821826
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficient drug approval and monitoring must rely on sound regulatory science.
    Meagher EA; Fitzgerald GA
    Nat Med; 2011 Dec; 17(12):1535. PubMed ID: 22146443
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical development of drugs for epilepsy: a review of approaches in the United States and Europe.
    Porter RJ; Baulac M; Nohria V
    Epilepsy Res; 2010 May; 89(2-3):163-75. PubMed ID: 20347575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing potential risks and evaluating expected benefits.
    Shaya FT; Gu A
    Manag Care Interface; 2005 May; 18(5):27-30. PubMed ID: 15941187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug safety. Gaps in the safety net.
    Couzin J
    Science; 2005 Jan; 307(5707):196-8. PubMed ID: 15653480
    [No Abstract]   [Full Text] [Related]  

  • 14. Multistakeholder Advice at the European Medicines Agency: Is It Still Needed?
    Vamvakas S; Moseley J; Vetter T
    Clin Pharmacol Ther; 2019 Apr; 105(4):819-821. PubMed ID: 30811587
    [No Abstract]   [Full Text] [Related]  

  • 15. The Human Genome Project in the United States: a perspective on the commercial, ethical, legislative and health care issues.
    Mackler BF; Barach M
    J Int Bioethique; 1991; 2(3):149-57. PubMed ID: 11654898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Avoiding pregnancy: "A plan" versus plan B.
    Rudd G
    Ann Pharmacother; 2004 Sep; 38(9):1535-6. PubMed ID: 15280516
    [No Abstract]   [Full Text] [Related]  

  • 17. Muddied messages about FDA.
    Miller HI
    Nat Biotechnol; 2003 Jul; 21(7):732-3. PubMed ID: 12833084
    [No Abstract]   [Full Text] [Related]  

  • 18. EU court gets tough on patent extensions for combo products.
    Waters H
    Nat Med; 2012 Jan; 18(1):4. PubMed ID: 22227647
    [No Abstract]   [Full Text] [Related]  

  • 19. Is having more preapproval data the best way to assure drug safety?
    Garber AM
    Health Aff (Millwood); 2008; 27(5):w371-3. PubMed ID: 18682442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory agency consideration of pharmacogenomics.
    Pendergast MK
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1498-503. PubMed ID: 18849547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.